palivizumab
Selected indexed studies
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (Pediatrics, 2024) [PMID:39350745]
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (Cochrane Database Syst Rev, 2021) [PMID:34783356]
- Palivizumab. (Drugs, 1999) [PMID:10473022]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (2024) pubmed
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (2021) pubmed
- Palivizumab. (1999) pubmed
- Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). (2024) pubmed
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (2025) pubmed
- Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. (2019) pubmed
- Palivizumab: an overview. (1999) pubmed
- Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review. (2024) pubmed
- Palivizumab prophylaxis in preterm infants. (2017) pubmed
- Palivizumab Use in the NICU: 1999-2020. (2022) pubmed